Nureca Limited FY26 Results: Revenue Jumps 28%, Turns Profitable Annually

FY26 Revenue (Standalone): ₹147.21 crore
FY26 Profit After Tax (Standalone): ₹0.30 crore

Reader Takeaway: Annual revenue growth and profitability turnaround overshadowed by Q4 non-operating loss; significant capex planned.

What just happened

Nureca Limited announced its standalone and consolidated financial results for the fiscal year ending March 2026 (FY26). The company reported a significant 28% year-over-year increase in standalone revenue from operations, reaching ₹147.21 crore, compared to ₹114.64 crore in FY25. This growth helped Nureca turn profitable on a full-year basis, posting a Profit After Tax (PAT) of ₹0.30 crore for FY26, a notable improvement from a loss of ₹0.67 crore in FY25.

Despite the positive annual performance, the fourth quarter (Q4 FY26) saw a standalone loss of ₹6.63 crore. This was primarily attributed to non-operating expenses, specifically a fair value change and net loss on investments amounting to ₹8.34 crore.

Why this matters

The annual results indicate a strengthening top-line and a successful turnaround in full-year profitability, suggesting improved operational efficiency. The approved ₹100 crore capex for manufacturing expansion signals management's confidence in future growth and its commitment to scaling up operations for medical devices, healthcare consumables, and hygiene products.

However, the Q4 loss highlights volatility from non-operating items, which investors should monitor. The CFO transition and board re-appointments also indicate ongoing corporate activity that could influence future strategy and governance.

The backstory

Nureca Limited is a diversified healthcare products company. In the quarter ended December 31, 2025, the company completed a share buyback of equity shares at ₹330 per share. The company also has a merger scheme with Nureca Technologies pending NCLT sanction.

What changes now

The approval of ₹100 crore capex for manufacturing expansion at its existing site in Sundran, Dera Bassi, Punjab, marks a significant strategic move. This investment is earmarked for expanding capabilities in producing medical devices, healthcare consumables, and hygiene products. The appointment of a new CFO and re-appointments of key leadership roles are also effective in the coming months, setting the stage for continued management oversight.

Risks to watch

The primary concern is the recurring impact of non-operating fair value losses on investments, which led to the quarterly loss in Q4 FY26. Investors will need to watch if these non-operating items continue to affect short-term profitability. The transition of the CFO role, with Mr. Naresh Gupta resigning and Mr. Chander Kant appointed, is another point to monitor for smooth leadership handover.

Peer comparison

Nureca operates in the medical devices and healthcare consumables sector. Competitors include companies like Poly Medicure, Dixon Technologies (in certain product segments), and other smaller players in the medical device manufacturing space. While direct financial comparisons are complex due to diverse product portfolios, Nureca's annual revenue growth of 28% and return to profitability appear positive in the context of a growing healthcare market.

Context metrics (time-bound)

• FY26 Revenue (Standalone): ₹147.21 crore (vs. ₹114.64 crore in FY25, up ~28%)
• FY26 PAT (Standalone): ₹0.30 crore (vs. ₹-0.67 crore in FY25)
• Q4 FY26 PAT (Standalone): ₹-6.63 crore (due to ₹8.34 crore in 'Other Expenses' from investment fair value changes)
• Capex Approved: ₹100 crore for manufacturing expansion
• CFO Change: Mr. Chander Kant appointed from June 27, 2026.
• AGM Date: July 28, 2026 (10th AGM).

What to track next

Investors should closely monitor the execution of the ₹100 crore manufacturing expansion project and its impact on future production capacity and revenue streams. The successful resolution of the merger scheme with Nureca Technologies pending NCLT approval will also be a key event. Tracking the company's ability to manage non-operating expenses and maintain profitability, especially in quarterly results, will be crucial.